JP3347200002

2026-06-01 Shionogi & Co.,Ltd. “Regarding the US FDA's approval of the anti-coronavirus (SARS-C … 続きを読む

2026-05-29 Shionogi & Co.,Ltd. “Regarding the approval of naldemedine, a treatment for opioid-induc … 続きを読む

2026-05-26 Shionogi & Co.,Ltd. “We have posted the "Notice of Convocation of the 161st Ordinar … 続きを読む

2026-05-26 Shionogi & Co.,Ltd. “We have posted a notice of partial correction to the Notice of Conv … 続きを読む

2026-05-19 Shionogi & Co.,Ltd. “Regarding the positive interim analysis results of the domestic Pha … 続きを読む

2026-05-15 Shionogi & Co.,Ltd. “We have posted the transcript of the FY2025 financial results brief … 続きを読む

2026-05-14 Shionogi & Co.,Ltd. “The results of the global Phase 3 post-exposure prevention trial (S … 続きを読む

2026-05-12 Shionogi & Co.,Ltd. “We have posted the financial results presentation materials for fis … 続きを読む

2026-05-12 Shionogi & Co.,Ltd. “We have posted our financial results summary and supplementary mate … 続きを読む

2026-04-28 Shionogi & Co.,Ltd. “Regarding our participation in the World Economic Forum and our sig … 続きを読む